Epidemiology, Healthcare Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Claims Data Analysis in Germany From 2016 to 2021
Speaker(s)
Obermueller D1, Berger K2, Klamroth R3, Kleppisch M4, Rauchensteiner S4, Ecke I5, Herrmann S5, Pawlowska-Phelan D6, Häckl D7, Kisser A5
1Ingef, Berlin, Berlin, Germany, 2Department of Medicine III, LMU Hospital,, Munich, Germany, 3Zentrum für Gefäßmedizin, Klinik für Innere Medizin – Angiologie und Hämostaseologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany, 4Pfizer Pharma GmbH, Berlin, Germany, 5Pfizer Pharma GmbH, Berlin, Berlin, Germany, 6InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, 7University of Leipzig, Health Economics and Management, Leipzig, SN, Germany
Presentation Documents
OBJECTIVES: The standard of care in Germany for patients with moderate - severe hemophilia is a lifelong prophylactic treatment with intravenous concentrated FVIII or FIX to prevent bleeding events. To assess the economic value of emerging treatment options studies describing the economic burden of hemophilia under current standard of care in Germany are needed. Here we present a structured approach classifying hemophilia patients by treatment regimen in administrative claims data to examine real-world economic burden of Hemophilia in Germany from 2016 to 2021.
METHODS: Hemophilia patients aged 12 years and older were identified in InGef statutory health insurance claims data via ICD-10 codes D66 (Hemophilia A, HA)and D67 (Hemophilia B, HB) in combination with ≥1 claim for hemophilia-related medication in the study year. Each patient’s factor regimen type was classified as either indicative of a severe phenotype predominantly requiring prophylactic treatment or a non-severe phenotype predominantly treated on-demand using a prespecified classification threshold of 100.000 IU for HA and 80.000 IU for HB (40.000 IU if patient had received extended-half-life factor products). HCRU and cost outcomes were captured for each study year and included all-cause hospitalizations, physician visits, and all cause and hemophilia-related medication.
RESULTS: Based on projected patient numbers, 2,748 to 3,337 treated HA patients and 566 to 802 treated HB patients were estimated from 2016 to 2021, with 43 to 53% and 40% to 56% categorized in the severe treatment group. In 2021, mean (SD) per-patient medication costs were €321,987 (€157,915) in the severe treatment group vs. €43,487 (€92,821) in non-severe group for HA and € 289,411 (€132,400) vs. €19,253 (€23,655) for HB.
CONCLUSIONS: The results demonstrate the high economic burden in severe HA and HB patients in Germany, driven by the need for continuous factor replacement therapy and give an estimate of treatment costs based on a real-world therapy mix.
Code
HSD54
Topic
Economic Evaluation, Epidemiology & Public Health
Disease
Genetic, Regenerative & Curative Therapies, Rare & Orphan Diseases, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)